Denosumab biosimilar (Alvotech Swiss)

地舒单抗生物类似药（Alvotech Swiss）

Report date: 2026/05/26 20:00:28

Base Information

Drug NameDenosumab biosimilar (Alvotech Swiss)
Drug Alias NameAcvybraXbonzyAVT-03AVT03
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsBone ResorptionOsteoporosis, PostmenopausalOsteoporosis +[5] 
Global Approved IndicationsBone ResorptionOsteoporosis, PostmenopausalOsteoporosis +[5] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2025/11/17
Country/TerritoryCzechiaBulgariaUnited States +[10] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAlvotech Swiss Ag
China Registration ClassN/A

Develop Information

Active CompaniesReddy Holding GmbhAlvotech Swiss AgStada Arzneimittel Ag
Inactive CompaniesN/A
Active IndicationsBone ResorptionOsteoporosis, PostmenopausalOsteoporosis +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A